Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
about
A review of malaria vaccine clinical projects based on the WHO rainbow tablePreclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxStructure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodiesProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaThe evolution of poxvirus vaccinesA novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicityExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVAPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsA viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityAdenoviral vectors as novel vaccines for influenza.Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.A novel oncolytic adenovirus based on simian adenovirus serotype 24A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.The influence of delivery vectors on HIV vaccine efficacyThe blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureTranslating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsT cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsA phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malariaSafety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated HostsDifferential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceIncidental diagnosis in healthy clinical trial subjectsCan growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?
P2860
Q21034112-63083A56-C976-4D97-8A39-5FCB4F6122F7Q24273364-95905DC5-5D99-4DFA-A5DA-F566FF35B92AQ24289322-C1375C28-EC67-4EBC-B76A-D0D127A28753Q26700012-5E7D38F4-E789-40B9-B9A1-95C3DC838117Q26772878-FA1B3955-9E83-4B5B-9BB6-02A082F4CD03Q26995905-7D0ED5BF-AC50-4AB4-A77E-9281A6E23727Q28727030-155F77C5-F062-4F1F-85E5-BF5730F787AAQ28727937-EACC60DC-8654-4121-BFAF-077448A8B79AQ28731894-F5CE70D9-7B83-4F81-8F44-DC7BE10B41CAQ28740771-06E4580F-A25B-4ED2-ABC2-E74D8B8B959CQ30370445-95AC8266-B420-4061-A8D3-4025B0E95584Q33586992-8E162FF1-C949-4AE5-8A61-404B8BEC526AQ33688856-D178CA61-563F-4861-95A2-90C046378342Q33724960-AAF6318F-D3D6-46C6-B743-C966A9E2E9F4Q33743457-A7E2A617-EE3A-485E-98FB-70E43C829A9AQ33798074-85EF44F3-57C8-4AF9-AAED-7B0412443D9CQ33875160-D4356CC6-3FAA-4928-9814-968AA7C53635Q34072792-889B0D02-8C8C-498D-9B56-46CD32CE63F4Q34077543-9F6B2966-8E44-43B7-902F-7902D646A5CCQ34241973-88B59B02-C432-4C69-8690-F6CB27EC6D96Q34257253-93A0B205-1519-4965-A83F-737C672AF1A8Q34301461-1ED3FFB2-FAFE-484D-8464-739D0A30AFC7Q34416263-B6867D14-66EA-4914-8E3D-F8E206B59B6AQ34600955-115E28BB-E9D1-451A-B958-5C9006FE4C0BQ34634002-751A780B-549C-4019-9B75-89737272A4BBQ34734075-BEFD025B-EDE7-4C8E-A2E1-610E4FFF1140Q34792326-57B51E68-E502-419A-A508-2525CCCC8FF4Q34978590-53717A40-D0CB-431D-9CD1-49327C2FE45FQ35021277-07C6D56E-76B5-4AEF-B975-F79098AF30CDQ35091556-61A3A81C-785F-4CBC-B5F0-AACCEA93E12AQ35163318-3AA45B2E-05B1-48D6-ABC8-2F44F79F78B0Q35557657-D192167C-21CB-4C0C-883F-11A17449EDA5Q35718341-C56AB7AF-3141-4983-90DA-FDBBB71E9ADDQ36043731-599A9B07-9D55-483A-A365-EAFFABF0DD7FQ36064542-E53C24AC-3A88-442F-94FF-1B0AE6054EB7Q36225504-3AA0421F-265A-4379-83EF-992E15EA0494Q36247867-6233519E-9B2E-432E-A047-1E050A793550Q36291682-093A7451-36F5-43F4-A658-936644CB62B4Q36301976-A07D6AB1-1051-4451-B35F-FBFD9E65B7EDQ36391845-2395FED8-3097-49B8-AA55-3D92DE4EB6F3
P2860
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@ast
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@en
type
label
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@ast
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@en
prefLabel
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@ast
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@en
P2093
P2860
P50
P356
P1433
P1476
Phase Ia clinical evaluation o ...... hAd63 and MVA vaccine vectors.
@en
P2093
Alfredo Nicosia
Alison M Lawrie
Christian Epp
Christopher J A Duncan
Eleanor Berrie
Ian D Poulton
Matthew D J Dicks
Riccardo Cortese
Samuel E Moretz
Sarah Moyle
P2860
P304
P356
10.1038/MT.2011.176
P50
P577
2011-08-23T00:00:00Z